🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

111 results for “Chongqing” Clear

  1. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  2. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  3. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  4. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  5. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  6. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  7. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  8. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  9. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  10. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial

  11. Melphalan flufenamide (Melflufen)

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  12. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  14. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial

  15. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  16. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial

  17. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

  18. PCN-101

    Chongqing Precision Biotech Co., Ltd

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  19. PDI-192

    Chongqing Precision Biotech Co., Ltd

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. PDI-320

    Chongqing Precision Biotech Co., Ltd

    Rosacea

    phase 2 small molecule active

    1 trial

  21. PRAX-222 - Initial Dose

    Chongqing Precision Biotech Co., Ltd

    SCN2A-DEE

    phase 2 small molecule active

    1 trial

  22. PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures

    phase 2 small molecule active

    1 trial

  23. Part A: 20 and 40 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  24. delolimogene mupadenorepvec

    Chongqing Precision Biotech Co., Ltd

    Malignant Melanoma

    phase 2 gene therapy completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources